**Question:** Topical Mitomycin C is useful in treatment of

A. Squamous cell carcinoma
B. Basal cell carcinoma
C. Bowen's disease
D. Psoriasis

**Core Concept:**
Mitomycin C is a chemotherapeutic agent widely used in oncology, particularly in the treatment of malignancies. It functions by inhibiting DNA synthesis and intercalating with DNA, preventing the replication and division of cells. Topical application is used in certain dermatological conditions as it has a more localized effect, reducing systemic side effects.

**Why the Correct Answer is Right:**
Topical Mitomycin C is specifically beneficial in the treatment of C. Bowen's disease. Bowen's disease, also known as Bowenoid papulosis or Bowen's syndrome, is a precursor to squamous cell carcinoma (option A) and basal cell carcinoma (option B). While Mitomycin C can be used in the management of these conditions, its primary role is to prevent the progression of Bowen's disease to invasive skin cancer.

**Why Each Wrong Option is Incorrect:**
Option A (Squamous cell carcinoma) and option B (Basal cell carcinoma) are both types of skin cancer, but Mitomycin C is not the preferred treatment for these conditions due to its limited penetration and potential systemic absorption. Option D (Psoriasis) is an inflammatory skin disorder, and Mitomycin C is not effective in its management.

**Why Mitomycin C is not appropriate for the treatment of psoriasis:**
Mitomycin C is not the first-line therapy for psoriasis as it is a chemotherapy drug with systemic effects that can cause severe side effects. For psoriasis, topical corticosteroids, vitamin D analogs, and calcipotriol are more suitable and effective treatments.

**Clinical Pearl:**
Topical Mitomycin C can serve as a potent chemopreventive agent in patients with Bowen's disease, reducing the risk of progression to invasive skin cancer. In such cases, it plays a crucial role in maintaining the integrity of the skin and preserving the patient's limb and life.

**Correct Answer:**
Correct Answer: C. Bowen's disease

---

**Core Concept:**
Mitomycin C is a chemotherapeutic agent primarily used in oncology to treat various types of cancer, including bladder, breast, colon, stomach, and ovarian cancer. In dermatology, it is used in the management of Bowen's disease, a precancerous condition characterized by keratinocyte dysplasia and epidermal atypia. Mitomycin C inhibits the replication of cells, preventing the progression of Bowen's disease to invasive squamous cell carcinoma.

**Why Mitomycin C is appropriate for Bowen's disease:**
1. Mitomycin C is a potent chemopreventive agent, effectively inhibiting the progression of Bowen's disease to invasive squamous cell carcinoma.
2. It is a topical application, which ensures local delivery and limits systemic absorption, reducing the risk of side effects associated with systemic chemotherapy.
3. Mitomycin C acts on the epidermis, targeting dysplastic keratinocytes, which helps maintain the